TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 150 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,537,162 | -26.2% | 171,942 | +26.9% | 0.00% | 0.0% |
| Q2 2023 | $2,081,863 | -26.1% | 135,538 | +8.2% | 0.00% | 0.0% |
| Q1 2023 | $2,816,468 | +77.9% | 125,232 | +66.3% | 0.00% | 0.0% |
| Q4 2022 | $1,583,412 | +0.3% | 75,293 | +17.5% | 0.00% | 0.0% |
| Q3 2022 | $1,579,000 | +188.1% | 64,082 | +183.5% | 0.00% | – |
| Q2 2022 | $548,000 | -1.8% | 22,601 | +4.4% | 0.00% | – |
| Q1 2022 | $558,000 | -15.8% | 21,644 | +1.4% | 0.00% | – |
| Q4 2021 | $663,000 | +28.7% | 21,346 | +0.5% | 0.00% | – |
| Q3 2021 | $515,000 | +238.8% | 21,238 | +103.8% | 0.00% | – |
| Q2 2021 | $152,000 | -47.6% | 10,422 | -10.3% | 0.00% | – |
| Q1 2021 | $290,000 | +7.4% | 11,613 | +17.4% | 0.00% | – |
| Q4 2020 | $270,000 | – | 9,895 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 895,821 | $8,008,640 | 3.99% |
| Deep Track Capital, LP | 7,370,000 | $65,887,800 | 2.54% |
| VR Adviser, LLC | 2,623,677 | $23,455,672 | 2.47% |
| Sio Capital Management, LLC | 884,770 | $7,909,844 | 2.45% |
| Kynam Capital Management, LP | 957,502 | $8,560,068 | 1.40% |
| MPM BioImpact LLC | 552,846 | $4,942,443 | 1.32% |
| ARMISTICE CAPITAL, LLC | 7,500,000 | $67,050,000 | 1.03% |
| Parkman Healthcare Partners LLC | 577,494 | $5,162,796 | 0.95% |
| Tri Locum Partners LP | 251,702 | $2,250,216 | 0.72% |
| Cheyne Capital Management (UK) LLP | 26,200 | $234,228 | 0.68% |